Uncategorised - European Medical Journal

Investigating Probiotics for Managing Atopic Dermatitis in Infants

Recent research highlights the role of gut microbiota in atopic dermatitis pathogenesis.

New Long-Term Solution for Chronic Hand Eczema

A recent phase 3 open-label extension study has demonstrated that delgocitinib cream is both safe and effective for long-term management of chronic hand eczema (CHE) in adults.

Comparing Immunosuppressants: What Works Best in Systemic Sclerosis?

A recent analysis from the RESOLVE-1 trial has highlighted the potential of mycophenolate mofetil (MMF) in treating diffuse cutaneous systemic sclerosis (dcSSc), particularly in early-stage disease.

Remdesivir and COVID-19: Are Treatment Guidelines Keeping Up?

A new systematic review and meta-analysis of over 1.3 million patients has confirmed that remdesivir significantly improves survival rates for hospitalized COVID-19 patients, yet treatment guidelines may not fully reflect this evolving evidence.

Why Diversity in Clinical Trials Matters More Than Ever

Increasing diversity in research, from basic science to clinical trials, remains essential for advancing equitable healthcare outcomes.

Stroke's Financial Toll on Families: New Insights

Financial challenges faced by family surrogate decision-makers of stroke patients were highlighted in a new study that revealed that nearly half experience moderate to severe concerns about affording stroke-related medical expenses.

Nemolizumab in Atopic Dermatitis

Nemolizumab is an anti-IL-31Rα monoclonal antibody that has demonstrated clinical efficacy in two global Phase III studies (ARCADIA-1 and…

Butter vs. Plant-Based Oils: Groundbreaking Study Reveals Butter Linked to Higher Death Rates

Butter linked to higher mortality; plant-based oils reduce death risks. Study urges dietary swaps for long-term health.

Cartoon brain on green background

Phase 2 trial begins for psychedelic-based depression treatment

A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.

Niraparib Shows Promise in Ovarian Cancer: ESGO 2025

The MITO 40 study, presented at ESGO 2025, highlights promising results for Niraparib as a maintenance treatment in ovarian cancer patients with no residual disease post-surgery.